The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R.sup.1 and R.sup.2 independently represent: a C.sub.1-6alkyl group; an optionally substituted (amino)C.sub.1-4alkyl-group; an optionally substituted non-aromatic C.sub.3-15carbocyclic group; a (C.sub.3-12cycloalkyl)C.sub.1-3alkyl-group; a group --(CH.sub.2).sub.r(phenyl).sub.s in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group --(CH.sub.2).sub.t Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or R.sup.1 represents H and R.sup.2 is as defined above; or R.sup.1 and R.sup.2 together with the nitrogen atom to which they are attached represent a saturated optionally substituted 5 to 8 membered heterocyclic group as defined above; X is CO or SO.sub.2; Y is absent or represents NH optionally substitututed by a C.sub.1-3alkyl group; R.sup.3 and R.sup.4 independently represent phenyl, thienyl or pyridyl substituted by Z; Z represents a C.sub.1-3alkyl group, a C.sub.1-3alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, trifluoromethylsulphonyl, nitro, amino, mono or di C.sub.1-3alkylamino, mono or di C.sub.1-3alkylamido, C.sub.1-3alkylsulphonyl, C.sub.1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C.sub.1-3alkyl carbamoyl, sulphamoyl and acetyl; and R.sup.5 is H, a C.sub.1-3alkyl group, a C.sub.1-3alkoxymethyl group, trifluoromethyl, a hydroxyC.sub.1-3alkyl group, C.sub.1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C.sub.1-3alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula --CONHNR.sup.aR.sup.b; with the provisos; and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

 
Web www.patentalert.com

< Human LXR.alpha. variants

> Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function

~ 00416